Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Roivant Sciences

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
From Roivant Sciences
Via GlobeNewswire
Tickers OGN ROIV
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
From Roivant Sciences
Via GlobeNewswire
Tickers OGN ROIV
Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Roivant Provides Update on Graves’ Disease Development Program
From Roivant Sciences
Via GlobeNewswire
Tickers IMVT ROIV
Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
From Roivant Sciences
Via GlobeNewswire
Tickers IMVT ROIV ROIVW
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
From Roivant Sciences
Via GlobeNewswire
Tickers RHHBY ROIV ROIVW
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
From Roivant Sciences
Via GlobeNewswire
Tickers IMVT ROIV ROIVW
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant
From Roivant Sciences
Via GlobeNewswire
Tickers RHHBY ROIV ROIVW
Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Announces Completion of Redemption of its Outstanding Warrants
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Announces Redemption of Outstanding Warrants
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.